Judge Rejects Biovail's Claim Construction In Diltiazem Patent Suit
A federal judge has declined to accept Biovail Laboratories Inc.'s claim construction for a key term in the drug maker's patent infringement lawsuit against Canadian generics maker Apotex over the extended-release...To view the full article, register now.
Already a subscriber? Click here to view full article